The “one and done” Johnson & Johnson coronavirus vaccine is . . . . done.
— Sheryl Gay Stolberg (@SherylNYT) June 18, 2021
Only 11.8 M doses administered. Millions will expire amid fears of a rare side effect. 10s of millions have been ditched b/c of problems at Emergent BioSolutions. @noahweiland https://t.co/x8fdjklbuk
Great job Fauci and Biden!
— Jason Miller (@JasonMillerinDC) June 18, 2021
“High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S.” https://t.co/THb19voAtz
Single-dose vaccine was seen as a breakthrough for reaching isolated and vulnerable Americans. But it fell flat, leaving millions of shots soon to expire, amid decreasing vaccine demand in US: 30 million doses of Pfizer and 25 million of Moderna are unusedhttps://t.co/C9GPK9PGzT
— Alfons López Tena (@alfonslopeztena) June 18, 2021
?When you contract w/manufacturers w/o mass production experience & manufacturing sites don't meet standards of cleanliness, trust not deserved
— ?Noelle: please no campaign $$ to DINOs (@NReveillee) June 18, 2021
Problems⬆️#ONEV1 #OVHealthcare
High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S. https://t.co/3vEdgr87US
“It’s just kind of one after another negative news about the vaccine,” a Michigan health official told @noahweiland : https://t.co/bvM5d7dyjc
— Sharon LaFraniere (@SharonLNYT) June 18, 2021
Good story from @noahweiland on how the one-and-done $JNJ vaccine became a disappointment: https://t.co/BPZFsiXslj
— Rebecca Robbins (@RebeccaDRobbins) June 18, 2021
High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S. https://t.co/OTxS0HNvxA
— Bo Snerdley (@BoSnerdley) June 18, 2021
The Belgian court ordered AstraZeneca to deliver 50 million doses of its coronavirus vaccine between now and late September, or pay a €10 fine per delayed dose.
— POLITICOEurope (@POLITICOEurope) June 18, 2021
https://t.co/Eclebaeeyd
The AstraZeneca-Commission ruling was a win-win.
— Jillian Deutsch (@DeutschJill) June 18, 2021
The EU won’t get its 300M vaccine doses by September, a big win for AstraZeneca.
But this case was never really about the doses for the Commission — it was about being right. https://t.co/oEC5fnpmvQ